With treatment up to 8 years, raloxifene has no impact on benign breast conditions, symptoms, or biopsies, according to extended data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. The findings were presented by investigators from Eli Lilly and Company at this year's NAMS meeting.
With treatment up to 8 years, raloxifene has no impact on benign breast conditions, symptoms, or biopsies, according to extended data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. The findings were presented by investigators from Eli Lilly and Company at this year's NAMS meeting.
Previous MORE analyses had found similar outcomes in postmenopausal women treated with 60 mg per day of raloxifene. The new analysis looked at 7,705 postmenopausal women who had received 60 or 120 mg/d of raloxifene in MORE and continued to receive 60 mg/d for an additional 4 years in CORE (Continuing Outcomes Relevant to Evista). At each clinic visit, reports of benign breast conditions, breast symptoms, and breast biopsies were collected through nonspecific questioning.
No statistically significant differences were found for conditions including cyst, fibrocystic breast disease, and discharge between the women who received raloxifene and those on placebo for up to 8 years.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More